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Abstract
Urticaria is a common mast cell–mediated dermatosis presenting with pruritic ery-
thematous superficial plaques also known as hives or wheals. Angioedema is an acute 
condition manifesting as localized edema affecting the skin and mucous membranes. 
In contrast with urticaria, itching is often absent, the skin appears normal and the edema 
occurs in deeper dermal and subcutaneous tissues in angioedema. Spontaneous urticaria 
can either be acute lasting less than 6 weeks or chronic with a duration of more than 
6 weeks. In acute urticaria cases, an underlying cause, mostly medications, foods and 
infections, may be found in approximately 50% of patients. However, spontaneous urti-
caria is generally idiopathic. First-line treatment option for both acute and chronic urti-
caria is non-sedating H
1
 antihistamines. Patients with recalcitrant disease are candidates 
for therapy with corticosteroids, immunosuppressives or omalizumab treatment. There 
are two different mechanisms causing angioedema. The first is mast cell mediated and 
is considered to be part of the spectrum of spontaneous or inducible urticarias. Patients 
present with angioedema alone or angioedema combined with urticaria. The second is 
bradykinin-induced angioedema, as observed in the hereditary angioedema and angio-
tensin-converting enzyme (ACE) inhibitor–induced angioedema.
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1. Introduction
Urticaria is a common mast cell–mediated dermatosis presenting with pruritic erythema-
tous superficial plaques also known as hives or wheals. There may be associated swelling in 
deep dermis or subcutaneous tissue leading to angioedema [1]. Angioedema is rather painful 
than pruritic and takes longer time to resolve in contrast to the wheals which usually disap-
pear within 24 hours [2, 3]. The disease has considerable impact on patients’ quality of life 
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with  dissatisfaction in private life and work being frequent [4]. Non-sedating H
1
 antihista-
mines are the first line therapy for both acute and chronic urticaria. Apart from angioedema 
which is part of the spectrum of urticaria, there is bradykinin-induced angioedema, such as 
that observed in the hereditary angioedema characterized by angioedema without wheals. 
Management of isolated angioedema differs from that of urticaria involving both preventive 
measures and treatment of acute attacks [5].
2. Classification
The current classification of urticaria is based upon the clinical course of the disease. Subtypes 
include spontaneous urticaria, physical urticarias and other urticaria types [2]. Spontaneous 
urticaria can either be acute lasting less than 6 weeks or chronic with a duration of more 
than 6 weeks. This arbitrary division for chronicity has been made as the etiologies and thus 
the clinical evaluation of acute and chronic urticaria vary considerably [3]. The physical and 
other urticaria types are elicited by external stimuli, such as heat, cold, pressure, vibration, 
friction, sunlight, water, etc. [6]. These two subtypes of urticaria are beyond the scope of 
this chapter.
3. Epidemiology
An episode of urticaria can occur in 15–25% of individuals at some point in their lifetime. 
Approximately 40% of patients with urticaria have wheals associated with angioedema and 
1–13% of patients present with isolated angioedema [3, 7]. Socioeconomic status, ethnicity 
and education do not have any clear influence on the prevalence of the disease [3].
At first all cases of urticaria are acute; 30% of them progress to become chronic [7]. Acute 
episodic form of urticaria commonly presents in infancy and childhood, particularly in atopic 
subjects [1, 8]. Chronic urticaria peaks in adulthood between 20 and 40 years of age affecting 
women two times more frequently than men [1, 3, 4]. About 0.5–1% of population has chronic 
spontaneous urticaria at a specific point in time [3].
4. Etiology and pathogenesis
Drugs, foods, viral and parasitic infections, insect stings and contact allergens are present 
among the most common causes of acute urticaria [8]. Drugs most commonly implicated in 
acute urticaria are antibiotics (penicillins and sulfonamides), nonsteroidal anti-inflammatory 
drugs, acetylsalicylic acid, opiates and narcotics. Foods, such as milk, eggs, nuts, fish and 
shellfish are common offenders, as well as food additives, such as tartrazine dyes, benzoic 
acid derivatives like sodium benzoate. Approximately 50% of cases of acute urticaria are 
idiopathic [5, 9].
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The relationship between stress and chronic spontaneous urticaria is not fully understood. 
There are reports showing stressful life events, such as loss of close family member, financial 
problems, major personal illness preceded onset or exacerbation of the disease in a consider-
able subset of patients with chronic spontaneous urticaria [10, 11]. Although many patients 
report stress to exacerbate their disease, there is a lack of well-controlled studies on this 
subject [3].
In 35–40% of patients with chronic urticaria, circulating immunoglobulin G (IgG) autoan-
tibodies against alpha subunit of the IgE receptors are found and in 5–10% of chronic urti-
caria patients, there is IgG antibody to IgE. This subtype of chronic urticaria is designated as 
chronic autoimmune urticaria [12]. The remainder of the patients with chronic urticaria is 
classified under the name of chronic idiopathic urticaria. In this form of urticaria, the mecha-
nism for stimulation of mast cells is unknown [5].
Pathophysiological mechanisms leading to formation of urticaria and angioedema can be 
immune-mediated, complement-mediated, non-immune–mediated and autoimmune-medi-
ated [13]. As in most cases of acute urticaria, immune-mediated urticaria is an IgE-mediated 
hypersensitivity reaction. This allergic reaction is commonly triggered in response to drugs, 
foods and insect bites [7, 13]. Complement activation leading to release of C3a, C4a and C5a 
can stimulate mast cells. Non-immune–mediated urticaria involves direct activation of mast 
cells by non-IgE mechanisms examples of which are physical stimuli, radiocontrast dyes, 
drugs, such as opiates and vancomycin. Autoimmune urticaria involves autoantibodies 
causing mast cell degranulation [12, 13]. As noted all mechanisms lead to activation of mast 
cells causing liberation of histamine, leukotriene C4 and prostaglandin D2. These vasoac-
tive mediators cause vasodilatation and extravasation of plasma from postcapillary venules. 
In 4–5 hours, an inflammatory cytokine response including tumor necrosis factor, interleukin 
4 and interleukin 5 recruits a perivascular inflammatory infiltrate. The result is the formation 
a pruritic urticarial plaque or angioedema [7].
5. Clinical features
Urticarial wheals consist of circumscribed erythematous plaques of various sizes with central 
swelling, with or without a surrounding flare (Figure 1). There is accompanying intense pru-
ritus or occasional burning sensations. Lesions typically have round to oval shape but occa-
sionally irregular, serpiginous or gyrate configurations may occur. Wheals are blanchable by 
diascopy. Individual lesions usually disappear within 1–24 hours without scarring but some 
lesions may take up to 48 hours to resolve [14–16]. Patients often report a poorly localized 
pruritus starting before the appearance of wheals [7]. Pruritus may impair sleep, private life 
and work leading to a diminished quality of life [4].
Angioedema is a descriptive term for abrupt onset of swellings of the deep dermis and sub-
cutaneous tissue. In contrast to edema, angioedema is asymmetrical and can occur on non-
dependent sites. Most common sites of involvement are the lips (Figure 2), tongue, eyelids 
and genitalia although any part of the body can be involved. Due to the tissue distention, 
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the lesions are usually painful rather than pruritic. Swellings of angioedema can be pink or 
skin-colored [9, 17, 18]. Involvement of the mucous membranes is a common feature. Stridor, 
abdominal pain, rarely intestinal obstruction may result from edema of respiratory or gastro-
intestinal tract. Lesions may take up to 72 hours to resolve [9, 18].
6. Prognosis
Cases of acute urticaria have a benign course with most patients being managed with conven-
tional treatments [8].
Figure 1. Typical urticarial plaques are observed on the leg of the patient.
Figure 2. Angioedema involving the lips.
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Studies concerning duration of chronic spontaneous urticaria have yielded varying results. 
However, it is clear that many patients are affected for more than one year and an important 
proportion of patients have a long-term course of the disease exceeding 5 years [3].
In chronic spontaneous urticaria, there are four factors that potentially predict long disease 
duration, namely disease severity, presence of angioedema, autoreactivity and combination 
with physical urticaria. Patients with moderate to severe disease tend to have a more per-
sistent disease as compared to patients with mild disease. Presence of angioedema with or 
without wheals in patients with chronic spontaneous urticaria predicts a longer course [3]. 
Autoreactivity, which is defined by a positive autologous serum skin test, reflects the finding 
of autoantibodies against IgE receptor or IgE. These patients have more severe disease with 
a longer duration and require higher doses of antihistamines to control disease activity than 
patients with negative autologous serum skin test [19]. Patients suffering from both chronic 
spontaneous urticaria and physical urticaria are likely to have longer disease duration in com-
parison with patients with chronic spontaneous urticaria alone [3].
7. Associated diseases
An increased prevalence of concomitant allergic diseases including rhinitis, asthma and 
atopic dermatitis is observed in cases of acute urticaria [8].
Chronic autoimmune urticaria is associated with antithyroid antibodies namely anti-micro-
somal and anti-thyroglobulin antibodies, observed in 27% of cases [12]. In patients with 
chronic urticaria, other autoimmune conditions such as vitiligo, type I diabetes mellitus, 
systemic lupus erythematosus and rheumatoid arthritis are more prevalent than in general 
population [5, 16].
Patients with chronic spontaneous urticaria often have concomitant physical urticaria that 
present with wheals lasting 2 hours or less [6].
Role of Helicobacter pylori infection in etiology of chronic autoimmune urticaria is still con-
troversial [5]. However, it has been shown that H. pylori infection may contribute to the exac-
erbation of urticaria and that 2 weeks long triple therapy for eradication of the bacteria led 
to improvement of symptoms. As most patients infected with H. pylori are asymptomatic, 
screening of chronic urticaria patients for the presence of H. pylori infection by a non-invasive 
test, such as urea breath test or fecal antigen test is recommended [20].
8. Diagnosis
A through history is the most important tool in the diagnosis of urticaria. Duration, timing 
and localization of lesions, history of a recent viral infection, recent insect bite, medica-
tions, suspected foods, associated systemic symptoms, such as fever and arthralgia, and 
response to previous treatments should be questioned [5, 13]. In majority of cases of acute 
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urticaria, history taking and physical examination is sufficient for the diagnosis. Further 
investigations are generally not required in patients with acute urticaria except those with 
a clinical history or physical examination suggesting an underlying cause, such as upper 
respiratory tract infection, food- or drug-induced urticaria [8]. Skin prick tests and serum-
specific IgE tests can be used to confirm allergic reaction to foods, latex and certain anti-
biotics [5].
In chronic urticaria, complete blood count, liver enzymes, urinalysis and thyroid function 
tests can be checked; however, these laboratory tests are of minor significance, if there is not a 
suspected underlying etiology for persistent urticarial lesions [13, 21].
Skin testing to aeroallergens can be of value only if the patient has concomitant allergic rhini-
tis and/or asthma. If the patient reports a specific food to be strongly related with the attacks, 
a serologic test to the specific food can be performed. Serologic testing would be more reliable 
than skin testing as an interpretation of wheal and flare response would be misleading in 
patients under recurrent bouts of urticaria [16].
Autologous serum skin test is a practical clinical test to detect circulating functional autoan-
tibodies in patients with chronic urticaria. The test is performed by intradermal injection of 
patient’s own serum obtained while the patient is symptomatic and injection of 0.9% saline on 
volar aspect of the forearm. It is of importance to stop antihistamines 2 days before applica-
tion. A positive autologous serum skin test is defined as a red serum-induced wheal having a 
diameter greater than 1.5 mm than the saline-induced wheal at 30 min. The test is performed 
when an immunomodulatory treatment is planned for patients with severe chronic urticaria. 
However, this is a controversial issue as the presence or absence of autoantibodies does not 
predict efficacy to most therapies [5, 16]. Basophil histamine release assays, western blot anal-
ysis or ELISA are also used to detect autoantibodies. However, these tests are sophisticated 
tests not readily available to most clinicians [22].
Urticaria activity score (UAS) is commonly used to assess disease activity and treatment 
response in patients with chronic urticaria. UAS is calculated based on the daily number 
of wheals (1–3 points) and the intensity of pruritus (0–3 points) and ranges from 0 to 6 [23]. 
UAS7 is calculated by summing UAS recorded by the patient on 7 consecutive days. A UAS7 
score of less than 7 indicates control of disease, whereas a score exceeding 28 indicates poorly 
controlled symptoms [24].
9. Histopathology
Skin biopsies of acute lesions demonstrate a minimal inflammatory infiltrate along with dila-
tation of small vessels, flattened rete pegs and swollen collagen fibers. Histology of chronic 
urticaria lesions reveals a perivascular cuffing by predominantly T lymphocytes and also 
monocytes, neutrophils, eosinophils and basophils [25].
Observation of fragmentation of neutrophils, red cell extravasation and swelling of endothe-
lial cells in persistent lesions points to the diagnosis of leukocytoclastic vasculitis [13].
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10. Differential diagnosis
Urticarial rash may be seen in the course of many diseases (Table 1). Urticaria and angioedema 
can be manifestations of underlying systemic diseases, such as collagenopathies, endocrinopa-
thies, tumors and hemolytic diseases [1].
Urticarial vasculitis is a rare condition mainly affecting adult females in 4th decade of life. 
It may manifest with urticarial plaques, which generally persist for 48–72 hours. Pain and 
tenderness is a common complaint. The wheals may resolve leaving residual purpuric or 
hyperpigmented discoloration of the skin. Underlying pathogenesis is a type III hypersensi-
tivity reaction mediated by immune complexes. It is mostly idiopathic, however cases associ-
ated with connective tissue diseases (systemic lupus erythematosus), infections (hepatitis B 
and hepatitis C), medications (diltiazem, fluoxetine, potassium iodide, etc.) and malignancies 
have been reported. In histopathology, leukocytoclastic vasculitis is seen with signs of vessel 
damage, such as leukocytoclasis and fibrinoid deposits around venules. In contrast to urti-
caria, immunofluorescence of the skin shows deposits of immunoglobulins and complement 
[26, 27].
Systemic mastocytosis is a rare disorder in which atypical mast cells proliferate in the liver, 
spleen, lymph nodes, bone marrow and other organs. Involvement of the skin manifests as 
wheals and itching [5].
Urticarial lesions that persist beyond 24 hours should warrant alternative diagnosis, such 
as erythema multiforme minor, morbilliform drug eruption, dermatitis herpetiformis and 
bullous pemphigoid [9]. Erythema multiforme minor is an acute condition that differs from 
urticaria with its persistent targetoid lesions, and is typically less pruritic than urticaria [13].
Urticarial rash in a young child accompanied by fever, edema of hands and feet and arthral-
gias should prompt a diagnosis of serum sickness-like reaction. In this condition, urticarial 
plaques usually have an associated ecchymotic pattern. Serum sickness-like reaction is a 
hypersensitivity reaction that is often due to medications or infections. It develops 1–3 weeks 
Urticarial vasculitis
Systemic mastocytosis
Erythema multiforme minor
Morbilliform drug eruption
Dermatitis herpetiformis
Bullous pemphigoid
Serum sickness-like reaction
Urticaria multiforme
Cryopyrin-associated periodic syndromes
Table 1. Differential diagnosis of urticaria.
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after the initial antigen exposure and has a self-limited course. Urticaria multiforme is also a 
hypersensitivity reaction marked with annular urticarial plaques and bruise-like areas simi-
lar to that seen in serum sickness-like reaction. The triggering factor is often a viral infection; 
urticarial lesions are preceded by 1–3 days of fever [28].
Cryopyrin-associated periodic syndromes are autoinflammatory diseases including familial 
cold autoinflammatory syndrome, Muckle-Wells syndrome and the neonatal onset multisys-
tem inflammatory disease. They present often early in infancy with a variable severity of 
clinical manifestations. Main symptoms are fever, arthralgias and skin involvement with urti-
caria-like nonpruritic lesions. Histopathologically, the perivascular infiltration is composed of 
polymorphonuclear cells in contrast with classical urticaria [29].
11. Management
Management of acute urticaria should initially focus on avoidance of any triggering fac-
tors, such as foods, drugs, insect venoms and latex. First-line treatment agents are antihis-
tamines, corticosteroids and immunomodulatory agents are reserved for patients resistant 
to antihistamines [5].
11.1. Antihistamines
For the first-line management of acute or chronic urticaria, second-generation H
1
 antihis-
tamines are used. Fexofenadine, desloratadine, loratadine, cetirizine and levocetirizine are 
the most commonly prescribed agents [5, 10]. Symptomatic relief with suppression of the 
pruritus and reduction of the number and size of wheals is the main goal of treatment. 
Loratadine and cetirizine can be used starting from 6 months of age and are also safe 
during pregnancy [9, 10]. Efficacy of antihistamines is often patient specific and none are 
consistently superior [16].
Antihistamines target H
1
 receptors located on endothelial cells and sensory nerves. First-
generation antihistamines (hydroxyzine, diphenhydramine and chlorpheniramine) can pen-
etrate central nervous system and thus have sedating effects lasting longer than 12 hours. 
However relief of pruritus is much short-lived and lasts only up to 6 hours. Older first-gen-
eration antihistamines are not recommended for the management of chronic urticaria in the 
European Guidelines because they place patients at risk for serious side-effects and drug inter-
actions. In contrast to first-generation antihistamines, the second-generation antihistamines 
are devoid of sedating and anticholinergic effects [30]. Similar to first-generation H
1
 antihis-
tamines, the use of H
2
 receptor blockers (cimetidine and ranitidine) are not recommended in 
European Guidelines.
Updosing of antihistamines is safe in therapy resistant patients. Fourfold higher doses of licensed 
doses of antihistamines should be used before considering other treatments [30]. However, 
according to US guidelines treatment by updosing second-generation H
1
 antihistamines can 
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substituted with an add-on treatment with other second-generation H
1
 antihistamines, H
2
 
antagonists, leukotriene receptor antagonists or first-generation H
1
 antihistamines as alternative 
second step treatment options [31].
11.2. Corticosteroids
Corticosteroids can be used in the management of antihistamine-resistant cases of acute urti-
caria and exacerbations of chronic spontaneous urticaria. Long-term therapy with cortico-
steroids is strictly dismissed because of the risk of side effects and development of tolerance. 
Oral corticosteroids such as 7 days of prednisone up to 40 mg/day are often used to alleviate 
symptoms unresponsive to antihistamines in chronic urticaria [5]. Likewise, addition of a 
brief course of prednisone to antihistamines in acute urticaria significantly improves symp-
tom control [32].
11.3. Leukotriene receptor antagonists
Leukotriene receptor antagonists, such as montelukast and zafirlukast, may have a role in the 
management of chronic urticaria. According to European Guidelines, leukotriene receptor 
antagonists may be considered in patients who do not respond to updosing of H
1
 antihista-
mines, although evidence is low as compared to cyclosporine or omalizumab [30, 33].
11.4. Immunosuppressives
Cyclosporine has been shown to be effective in the treatment of recalcitrant cases of chronic 
spontaneous urticaria in combination with second-generation antihistamines especially cetiri-
zine. Its mechanism of action depends on the inhibition of anti-IgE–induced histamine release 
from basophils and skin mast cells. Cyclosporine at 3–5 mg/kg/day is administered with mon-
itorization of diastolic blood pressure and levels of serum creatinine, serum potassium, serum 
bilirubin and liver enzymes at each visit [34, 35]. Common adverse effects of cyclosporine 
therapy include hypertension, fatigue, gastrointestinal problems and headache [33].
Immunosuppressive therapy with mycophenolate, tacrolimus and methotrexate can also be 
considered in recalcitrant cases [31].
11.5. Omalizumab
Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E antibody 
that prevents binding of IgE to the high-affinity IgE receptor and thus prevents urticaria and 
angioedema. This new biologic treatment, applied by monthly subcutaneous injections in a 
standardized protocol, provides a rapid and effective control of treatment-refractory urticaria 
patients. Omalizumab is generally well-tolerated and safe. Major risks of omalizumab treat-
ment include anaphylaxis, increased risk of cardiac and neurovascular events, and a contro-
versial increased risk of lymphoma [16, 36, 37].
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11.6. Phototherapy
Efficacy of phototherapy, both narrowband UVB and PUVA, has been shown in several stud-
ies. Phototherapy is not recommended in urticaria guidelines; still it appears to be a safe and 
effective therapeutic modality for patients with refractory chronic urticaria [38–40].
12. Angioedema without wheals
As described previously in this chapter, angioedema is defined as swellings of the deep 
dermis and subcutaneous tissue. Clinically, there is non-pitting asymmetrically distributed 
edema usually involving the face. Angioedema typically resolves spontaneously in less than 
72 hours [41].
Clinically a variety of conditions may cause swellings that resemble angioedema. Acute con-
tact dermatitis develops after exposure to a foreign substance. When acute contact dermatitis 
involves the face, it is frequently misdiagnosed as angioedema. Abrupt onset of angioedema 
associated with diffuse maculopapular rash, fever, eosinophilia and lymphadenopathy is seen 
in drug rash with eosinophilia and systemic symptoms (DRESS) Syndrome. Periorbital edema 
of dermatomyositis may mimic angioedema [41]. Other diseases to consider in differential 
diagnosis of angioedema are superior vena cava syndrome, myxedema of hypothyroidism, 
photodermatitis, Crohn’s disease of the mouth and lips, facial cellulitis and Melkersson-
Rosenthal syndrome [18, 41].
Angioedema without wheals can be classified as hereditary angioedema, acquired angio-
edema, drug-induced angioedema and idiopathic angioedema [42].
12.1. Hereditary angioedema
12.1.1. Epidemiology
Hereditary angioedema is rare genetic disease with a prevalence of about 1:10,000–
1:50,000. The inheritance is autosomal dominant. In 20% of cases, a positive family his-
tory of the disease cannot be obtained because these cases occur due to spontaneous 
mutations [42].
12.1.2. Etiology and pathogenesis
Two types of the disease have been defined, both concerning the inhibitor of the first compo-
nent of human complement (C1). Type I accounts for 80–85% of cases and is characterized by 
low C1 inhibitor levels and function. Type II comprises the remaining 15–20% of cases and it 
is associated with normal levels of poorly functioning C1 inhibitor. Both types of hereditary 
angioedema result in low levels of C4; during acute attacks C2 levels may also decrease [42].
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The recently described hereditary angioedema type III is not associated with C1 inhibitor 
deficiency or dysfunction. The etiology of this very rare type of hereditary angioedema is not 
fully understood. It mostly affects women. Estrogens and mutations in factor XII are thought 
be involved in pathogenesis [43, 44].
C1 inhibitor is the major regulator of complement and contact system activation. With the 
decreased activity of C1 inhibitor, unopposed activation of contact system leads to generation 
of bradykinin. Bradykinin induces relaxation in vascular smooth muscle and increases vascu-
lar permeability causing angioedema [42, 44].
Trauma, stress, infection, menstruation, oral contraceptives, hormonal replacement therapy 
and angiotensin-converting enzyme (ACE) inhibitors can trigger the attacks. However an 
underlying trigger cannot be found in most of the cases [42, 44].
12.1.3. Clinical features
Clinically angioedema mostly involves the face, tongue and lips, abdomen, larynx, 
extremities and genitalia [42]. Any part of the body can be affected including chest, joints, 
muscles, etc. Abdominal colicky pain, nausea and vomiting are manifestations of gastroin-
testinal involvement. Edema of the upper airway tract can be life threatening [42, 43]. The 
onset of disease is usually in childhood mostly between 8 and 12 years. Episodic swellings 
last 1–5 days before subsiding. A serpiginous rash called erythema marginatum, fatigue 
and muscle aches are prodromal symptoms reported by 50% of patients with hereditary 
 angioedema [44].
12.1.4. Prophylaxis and treatment
Management of hereditary angioedema can be classified under three different categories, which 
are treatment of the attacks, short-term or procedural prophylaxis and long-term prophylaxis [43].
Management of acute attacks can be accomplished by replacement of C1 inhibitor or alter-
natively by using icatibant or ecallantide. Plasma-derived or recombinant C1 inhibitors are 
available for intravenous replacement of C1 inhibitor. Icatibant is bradykinin B2 receptor 
antagonist. Human C1 inhibitors and icatibant are approved for self-administration. These 
agents are most effective when given as early as possible during the attacks. Ecallantide works 
by reversible inhibition of kallikrein and is approved by FDA for use in patients older than 12 
years of age. Application by a healthcare professional is imperative because of a high risk of 
developing anaphylactic reaction [43].
As noted above trauma is among the well-known triggers of an angioedema attack. Thus a 
short-term prophylaxis is indicated before interventions in the upper aerodigestive tract, such 
as intubation, bronchoscopy or esophagogastroduodenoscopy. For this purpose C1 inhibi-
tors are the first-choice agents. Androgens, which have been the mainstay of management 
of patients with hereditary angioedema in the past, are no longer considered as first-line 
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options because of associated side effects and are only used when C1 inhibitor therapy is not 
available. Weight gain, hepatotoxicity, virilism and hypertension are among the various side 
effects of androgen therapy [43, 44].
Long-term prophylaxis can be initiated if treatment of acute attacks does not result in adequate 
symptom control. C1 inhibitor concentrates are recommended as first-line agents. Androgens 
and tranexamic acid are less favored because of high risk of adverse effects and low treatment 
efficacy, respectively [43].
12.2. Acquired angioedema
12.2.1. Etiology and pathogenesis
Acquired angioedema is an autoimmune disease characterized by autoantibodies against C1 
inhibitor [44]. A lymphoproliferative disorder such as non-Hodgin lymphoma or monoclonal 
gammopathy or an autoimmune disease is found in many of the cases. These associations 
suggest that pathological B cell clones may be responsible for acquired angioedema [45].
Acquired angioedema is divided into two types. Type I acquired angioedema is due to mas-
sive consumption of C1 inhibitor, presumably by tumor-related immune complexes. Type II 
acquired angioedema occurs due to the production of anti-C1 inhibitor autoantibodies [25].
12.2.2. Clinical features
Clinical features of acquired angioedema are similar to those seen in hereditary angioedema. 
Abdominal involvement is less frequent [44]. Absence of family history and late onset of 
symptoms at 4th decade are distinguishing features [42]. Laboratory evaluation of patients 
with acquired angioedema reveals low C4 levels and decreased C1 inhibitor activity similar 
to hereditary angioedema; but also decreased levels of C1q [44].
12.2.3. Treatment
Treatment of acquired angioedema mostly depends on treatment of the underlying disease 
[42]. Although response rates are low, treatments used for hereditary angioedema are fre-
quently applied. Acute attacks can be managed by administration of C1 inhibitor concentrate 
or alternatively by using icatibant or ecallantide. High-dose corticosteroid therapy is used in 
order to reduce production of autoantibodies but it is frequently ineffective and has many 
adverse effects. Rituximab has also been shown to be effective in decreasing autoantibody 
production against C1 inhibitor. Although several reports of patients successfully treated 
with rituximab exist, the responses can be inconsistent [44, 46].
12.3. Drug-induced angioedema
Drug-induced angioedema is most typically associated with the use of angiotensin-convert-
ing enzyme (ACE) inhibitors. Angiotensin receptor blockers, nonsteroidal anti-inflammatory 
drugs, fibrinolytics and oral contraceptives can also induce isolated angioedema [18].
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Angioedema due to angiotensin-converting enzyme inhibitors occurs in 0.1–6% of patients 
under treatment with ACE inhibitors. It tends to develop more commonly in women, smokers 
and in patients of African American descent [47]. ACE inhibitor angioedema mostly develops 
at the first month of treatment but may also occur years after starting the medication [42].
As the underlying mechanism involves elevated levels of bradykinin, antihistamines and 
corticosteroids are not helpful in the management of drug-induced angioedema. Although 
not FDA-approved for this indication, bradykinin receptor antagonist icatibant and kallikrein 
inhibitors are effective treatment agents [42, 48].
12.4. Idiopathic angioedema
The term idiopathic angioedema is used when there is no identifiable cause for the recurrent 
angioedema attacks without wheals. Idiopathic angioedema is a diagnosis of exclusion. C1 
inhibitor deficiency, factor XII mutation, treatment with ACE inhibitors must be ruled out 
[49]. The condition is mostly well-controlled with prophylactic antihistamines [5].
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